PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278971ArticlesСтатьиOMEGA-3 POLYUNSATURATED FATTY ACIDS: TOWARDS A STATUS OF SELF-DIRECTED STRATEGY FOR IMPROVING THE CARDIOVASCULAR PROGNOSISОМЕГА-3-ПОЛИНЕНАСЫЩЕННЫЕ ЖИРНЫЕ КИСЛОТЫ: НА ПУТИ К СТАТУСУ САМОСТОЯТЕЛЬНОЙ СТРАТЕГИИ УЛУЧШЕНИЯ СЕРДЕЧНО-СОСУДИСТОГО ПРОГНОЗАFominViktor ViktorovichФоминВиктор Викторович

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России

FominV VГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России200720111814NO14 (2011)№14 (2011)424524022023Copyright ©; 2011, Bionika MediaCopyright ©; 2011, ООО «Бионика Медиа»2011Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278971

The article presents the results of clinical studies that have examined the possibility of additional effect of antihyperlipidemic agents (statins, polyunsaturated fatty acids) on the prognosis in patients with chronic heart failure (CHF). The role of ω-3 polyunsaturated fatty acids in the prevention of cardiovascular complications, including ventricular arrhythmias and sudden death in patients with heart failure and coronary heart disease is demonstrated.

Представлены результаты клинических исследований, в которых изучалась возможность дополнительного влияния антигиперлипидемических препаратов (статинов, полиненасыщенных жирных кислот) на прогноз больных хронической сердечной недостаточностью (ХСН). Показана роль ω-3 полиненасыщенных жирных кислот в профилактике сердечно-сосудистых осложнений, в частности желудочковых аритмий и внезапной смерти у больных ХСН, а также ишемической болезнью сердца.

ω-3 polyunsaturated fatty acidschronic heart failureventricular fibrillationsudden deathω-3 полиненасыщенные жирные кислотыхроническая сердечная недостаточностьфибрилляция желудочковвнезапная смертьKjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357(22):2248-61.Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9645):1231-39.McMurray JJ, Kjekshus J, Gullestad L, et al. CORONA Study Group. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009;120(22):2188-96.Cleland JG, McMurray JJ, Kjekshus J, et al. CORONA Study Group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009;54(20):1850-59.De Caterina R, Madonna R, Zucchi R, La Rovere MT. Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. Am. Heart J 2003;146(3):420-30.Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372(9645):1223-30.Ghio S, Scelsi L, Latini R, et al.; GISSI-HF investigators. Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur. J. Heart Fail 2010;12(12):1345-53.Finzi AA, Latini R, Barlera S, et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca (GISSI-HF) trial. Am. Heart J 2011;161(2):338-43.Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354(9177):447-55.Marchioli R, Barzi F, Bomba E, et al.; GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105(16):1897-903.Marchioli R, Marfisi R.M, Borrelli G, et al. Efficacy of n-3 polyunsaturated fatty acids according to clinical characteristics of patients with recent myocardial infarction: insights from the GISSI-Prevenzione trial. J Cardiovasc Med (Hagerstown) 2007;8 Suppl 1:34-7.Aarsetøy H, Pönitz V, Nilsen OB, et al. Low levels of cellular omega-3 increase the risk of ventricular fibrillation during the acute ischaemic phase of a myocardial infarction. Resuscitation 2008;78(3):258-64.Aarsetoey H, Aarsetoey R, Lindner T, et al. Low levels of the omega-3 index are associated with sudden cardiac arrest and remain stable in survivors in the subacute phase. Lipids 2011;46(2):151-61.Moertl D, Hammer A, Steiner S, et al. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am. Heart J 2011;161(5):915-19.Richardson ES, Iaizzo PA, Xiao YF, Electrophysiological mechanisms of the anti-arrhythmic effects of omega-3 fatty acids. J Cardiovasc Transl Res 2011;4(1):42-52.Streppel MT, Ocké MC, Boshuizen HC, et al. Long-term fish consumption and n-3 fatty acid intake in relation to (sudden) coronary heart disease death: the Zutphen study. Eur Heart J 2008;29(16):2024-30.